Merck Gets Positive EU CHMP Opinion For KEYTRUDA Plus Padcev To Treat Resectable MIBC

Merck said the European Medicines Agency's CHMP issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv). The recommendation is a favorable regulatory milestone for Merck's oncology franchise and could expand the commercial opportunity for the combination in Europe, subject to final European Commission approval.